SCHEMBL923404

SCHEMBL923404

Cc1ccc(N)cc1N1CCOCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.62
GAA P10253 4/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
BRAF P15056 2/20 0.52
ALDH1A1 P00352 3/20 0.50
LMNA P02545 3/20 0.50
KDM4E B2RXH2 3/20 0.50
RAF1 P04049 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
THRB P10828 1/20 0.50
NR4A1 P22736 1/20 0.50
PTK2B Q14289 1/20 0.50
CASP1 P29466 1/20 0.50
LGMN Q99538 2/20 0.49
NSD2 O96028 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL519230 0.86 MAPT (0.69) MAPTGAASMN1; SMN2BRAFALDH1A1
SCHEMBL3341828 0.83 ALDH1A1 (0.70) MAPTGAASMN1; SMN2ALDH1A1LMNA
SCHEMBL3885064 0.81 KMT2A (0.53) MAPTGAASMN1; SMN2ALDH1A1LMNA
SCHEMBL14280213 0.81 LGMN (0.71) MAPTGAASMN1; SMN2BRAFALDH1A1
SCHEMBL13182855 0.80 LGMN (0.64) MAPTGAASMN1; SMN2ALDH1A1LMNA
SCHEMBL429632 0.80 MAPT (0.62) MAPTGAASMN1; SMN2ALDH1A1LMNA
SCHEMBL2302770 0.79 LGMN (0.50) MAPTGAASMN1; SMN2BRAFALDH1A1
SCHEMBL19088579 0.79 NPSR1 (0.58) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL20349156 0.79 ALDH1A1 (0.49) MAPTGAASMN1; SMN2ALDH1A1LMNA
SCHEMBL27742410 0.79 ALDH1A1 (0.52) MAPTGAASMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2828339-B1 CARBOXYLATE DYES MILLIKEN & CO (US) 2018-10-31 EP disclosed
US-9187717-B2 Carboxylate dyes MILLIKEN & COMPANY (US) 2015-11-17 US disclosed
US-20150099869-A1 Carboxylate Dyes MILLIKEN & COMPANY 2015-04-09 US disclosed
EP-2828339-A1 CARBOXYLATE DYES Milliken & Company (US) 2015-01-28 EP disclosed
EP-2828340-A1 LAUNDRY CARE COMPOSITIONS CONTAINING DYES The Procter & Gamble Company (US) 2015-01-28 EP disclosed
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
WO-2013142486-A1 LAUNDRY CARE COMPOSITIONS CONTAINING DYES THE PROCTER & GAMBLE COMPANY (US) 2013-09-26 WO disclosed
WO-2013142495-A1 CARBOXYLATE DYES MILLIKEN & COMPANY (US) 2013-09-26 WO disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 US disclosed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed
EP-1450791-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Kinetek Pharmaceuticals, Inc. (CA) 2004-09-01 EP disclosed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 WO disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MAPT 4573/4885GAA 1621/4885SMN1; SMN2 4161/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 MAPT 4573/4885GAA 1621/4885SMN1; SMN2 4161/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC MAPT 4000/4885GAA 2285/4885SMN1; SMN2 2243/4885
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C MAPT 4486/4885GAA 1927/4885SMN1; SMN2 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.